Next Generation Gene Therapy for the Treatment of Chronic Myocardial Ischemia and Heart Failure

Información del proyecto

HeartGenes

Identificador del acuerdo de subvención: 884382

DOI

10.3030/884382

Fecha de la firma de la CE 9 Junio 2020

Fecha de inicio 1 Mayo 2021

Fecha de finalización 31 Enero 2027

Financiado con arreglo a

• EXCELLENT SCIENCE - European Research Council (ERC)

Coste total

€ 2 500 000,00

Aportación de la UE

€ 2 500 000,00

Coordinado por

ITA-SUOMEN YLIOPISTO
Finland

CORDIS proporciona enlaces a los documentos públicos y las publicaciones de los proyectos de los programas marco HORIZONTE.

Los enlaces a los documentos y las publicaciones de los proyectos del Séptimo Programa Marco, así como los enlaces a algunos tipos de resultados específicos, como conjuntos de datos y «software», se obtienen dinámicamente de OpenAIRE .

Publicaciones

Peer reviewed articles (17)

Insights into Prime Editing Technology: A Deep Dive into Fundamentals, Potentials, and Challenges

Autores: Seyed Younes Hosseini, Rahul Mallick, Petri Mäkinen, Seppo Ylä-Herttuala
Publicado en: Human Gene Therapy, Edición 35, 2024, Página(s) 649-668, ISSN 1043-0342
Editor: Mary Ann Liebert Inc.
DOI: 10.1089/hum.2024.043

VEGF-B is a novel mediator of ER stress which induces cardiac angiogenesis via RGD-binding integrins independent of VEGFR1/NRP activities

Autores: Rahul Mallick, Ahmed B. Montaser, Henna Komi, Greta Juusola, Annakaisa Tirronen, Erika Gurzeler, Maria Barbiera, Petra Korpisalo, Tetsuya Terasaki, Tiina Nieminen, Seppo Ylä-Herttuala
Publicado en: Molecular Therapy, Edición 33, 2025, Página(s) 3242-3256, ISSN 1525-0016
Editor: Nature Publishing Group
DOI: 10.1016/j.ymthe.2025.03.012

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Autores: Korpela H., Siimes S., Ylä-Herttuala S.
Publicado en: JoVE Journal of Visualized Experiments, 2021, ISSN 1940-087X
Editor: MYJoVE Corporation
DOI: 10.3791/62833

Adenoviral VEGF-B186R127S gene transfer induces angiogenesis and improves perfusion in ischemic heart

Autores: Korpela Henna, Hätinen Olli-Pekka, Nieminen Tiina, Mallick Rahul, Toivanen Pyry, Airaksinen Jonna, Valli Kaisa, Hakulinen Mikko, Poutiainen Pekka, Nurro Jussi, Ylä-Herttuala Seppo
Publicado en: iScience, 2021, ISSN 2589-0042
Editor: Elsevier
DOI: 10.1016/j.isci.2021.103533

Long-term continuous monitoring of arrhythmias in pigs with insertable cardiac monitors

Autores: Jonna Airaksinen, Satu Siimes, Juha Hartikainen, Seppo Ylä-Herttuala
Publicado en: Pflügers Archiv - European Journal of Physiology, Edición 476, 2024, Página(s) 1145-1154, ISSN 0031-6768
Editor: Springer Verlag
DOI: 10.1007/s00424-024-02962-9

Characterization of a new IN-I-PpoI fusion protein and a homology-arm containing transgene cassette that improve transgene expression persistence and 28S rRNA gene-targeted insertion of lentiviral vectors

Autores: Alisa Nousiainen; Diana Schenkwein; Seppo Ylä-Herttuala
Publicado en: PlosOne, Edición 1, 2023, ISSN 1932-6203
Editor: Public Library of Science
DOI: 10.1371/journal.pone.0280894

Capillary Dynamics Regulate Post-Ischemic Muscle Damage and Regeneration in Experimental Hindlimb Ischemia

Autores: Galina Wirth; Greta Juusola; Santeri Tarvainen; Johanna P. Laakkonen; Petra Korpisalo; Seppo Ylä-Herttuala
Publicado en: Cells; Volume 12; Edición 16; Pages: 2060, Edición 3, 2023, ISSN 2073-4409
Editor: Basel MDPI AG
DOI: 10.3390/cells12162060

Low dose Adenoviral Vammin gene transfer induces myocardial angiogenesis and increases left ventricular ejection fraction in ischemic porcine heart

Autores: Niko Järveläinen, Paavo J. Halonen, Jussi Nurro, Antti Kuivanen, Juho Pajula, Miikka Tarkia, Maria Grönman, Antti Saraste, Johanna Laakkonen, Pyry Toivanen, Tiina Nieminen, Tuomas T. Rissanen, Juha
Publicado en: Scientific Reports, Edición 14, 2024, ISSN 2045-2322
Editor: Nature Publishing Group
DOI: 10.1038/s41598-024-81773-5

AAV2-VEGF-B gene therapy failed to induce angiogenesis in ischemic porcine myocardium due to inflammatory responses

Autores: Henna Korpela, Jaakko Lampela, Jonna Airaksinen, Niko Järveläinen, Satu Siimes, Kaisa Valli, Tiina Nieminen, Minttu Turunen, Maria Grönman, Antti Saraste, Juhani Knuuti, Mikko Hakulinen, Pekka Poutiainen, Vesa Kärjä, Jussi Nurro, and Seppo Ylä-Herttuala
Publicado en: Gene Therapy, 2022, ISSN 0969-7128
Editor: Nature Publishing Group
DOI: 10.1038/s41434-022-00322-9

Deletion of the murine ortholog of human 9p21.3 locus promotes atherosclerosis by increasing macrophage proinflammatory activity

Autores: Kettunen S, Ruotsalainen AK, Örd T, Suoranta T, Heikkilä J, Kaikkonen MU, Laham-Karam N, Ylä-Herttuala S
Publicado en: Frontiers in Cardiovascular Medicine, 2023, ISSN 2297-055X
Editor: Frontiers Media
DOI: 10.3389/fcvm.2023.1113890

Role of non-coding RNAs in physiological and pathological angiogenesis

Autores: Nihay Laham-Karam; Isidore Mushimiyimana; Krista Hokkanen; Seppo Ylä-Herttuala
Publicado en: Current Opinion in Physiology, Edición 1, 2023, ISSN 2468-8673
Editor: Elsevier
DOI: 10.1016/j.cophys.2023.100690

Critical limb-threatening ischaemia and microvascular transformation: clinical implications

Autores: Santeri Tarvainen; Galina Wirth; Greta Juusola; Olli Hautero; Kari Kalliokoski; Tanja Sjöros; Veikko Nikulainen; Jouni Taavitsainen; Jarkko Hytönen; Crister Frimodig; Krista Happonen; Tuomas Selander; Tomi Laitinen; Harri H Hakovirta; Juhani Knuuti; Nihay Laham-Karam; Juha Hartikainen; Kimmo Mäkinen; Seppo Ylä-Herttuala; Petra Korpisalo
Publicado en: European Heart Journal - Quality of care and clinical outcomes, Edición 5, 2023, ISSN 2058-1742
Editor: Oxford University Press
DOI: 10.1093/eurheartj/ehad562

Novel Designed Proteolytically Resistant VEGF-B186R127S Promotes Angiogenesis in Mouse Heart byRecruiting Endothelial Progenitor Cells

Autores: Rahul Mallick, , Erika Gurzeler, Pyry I. Toivanen, Tiina Nieminen and Seppo Ylä-Herttuala
Publicado en: Frontiers in Bioengineering and Biotechnology, 2022, ISSN 2296-4185
Editor: Frontiers
DOI: 10.3389/fbioe.2022.907538

Optimizing feasibility and reproducibility of pacing-induced heart failure model in pigs

Autores: Jaakko Lampela, Niko Järveläinen, Anni Määttä, Satu Siimes, Minja Heikkilä, Hanna Wang, Jarkko Kuivalainen, Juho Liljeström, Ville Vepsäläinen, Juha Hartikainen, Seppo Ylä-Herttuala
Publicado en: Scientific Reports, Edición 15, 2025, ISSN 2045-2322
Editor: Nature Publishing Group
DOI: 10.1038/s41598-025-98838-8

Strategies to improve safety profile of AAV vectors

Autores: Tuisku Suoranta, Nihay Laham-Karam and Seppo Ylä-Herttuala
Publicado en: Frontiers in Molecular Medicine, 2022, ISSN 2674-0095
Editor: Frontiers Media SA
DOI: 10.3389/fmmed.2022.1054069

Epigenetic drug screening identifies enzyme inhibitors A-196 and TMP-269 as novel regulators of sprouting angiogenesis

Autores: M. Beter, H. H. Pulkkinen, T. Örd, A. Sormunen, L. Kilpeläinen, J. E. Dunford, M. U. Kaikkonen, E. Aavik, N. Laham-Karam, U. Oppermann, J. P. Laakkonen, S. Ylä-Herttuala
Publicado en: Scientific Reports, Edición 15, 2025, ISSN 2045-2322
Editor: Nature Publishing Group
DOI: 10.1038/s41598-024-84603-w

Cardiac vein retroinjections provide an efficient approach for global left ventricular gene transfer with adenovirus and adeno-associated virus

Autores: Jaakko Lampela, Juho Pajula, Niko Järveläinen, Satu Siimes, Nihay Laham-Karam, Antti Kivelä, Isidore Mushimiyimana, Jussi Nurro, Juha Hartikainen, Seppo Ylä-Herttuala
Publicado en: Scientific Reports, Edición 14, 2024, ISSN 2045-2322
Editor: Nature Publishing Group
DOI: 10.1038/s41598-024-51712-5

Non-peer reviewed articles (1)

RNA interference-based therapies for the control of atherosclerosis risk factors

Autores: Sanna Kettunen, Anna-Kaisa Ruotsalainen, Seppo Ylä-Herttuala
Publicado en: Current Opinion in Cardiology, 2022, ISSN 0268-4705
Editor: Lippincott Williams & Wilkins Ltd.
DOI: 10.1097/hco.0000000000000972